Lunit Showcases Groundbreaking AI Insights into Lung Cancer at WCLC 2026
Lunit Showcases Groundbreaking AI Insights into Lung Cancer at WCLC 2026
Lunit, a prominent South Korean company focused on integrating AI into cancer diagnostics and precision oncology, recently presented three insightful studies at the World Conference on Lung Cancer (WCLC 2026), held in Seoul from September 12 to 15. These studies emphasized the significance of the tumor microenvironment (TME) in understanding non-small cell lung cancer (NSCLC) and its interactions with genomic mutations and treatment effectiveness.
In the first study, researchers employed Lunit SCOPE IO, an advanced AI platform, to analyze whole-slide images stained with hematoxylin and eosin from 494 cases of EGFR-mutant NSCLC. Interestingly, the analysis unveiled distinct TME characteristics associated with different mutation subtypes. Specifically, tumors with the exon 19 deletion (Ex19del) exhibited a lower density of intratumoral tumor-infiltrating lymphocytes (TILs), indicating an immune response disparity compared to L858R mutation tumors, which had a higher infiltration of both TILs and macrophages. Additionally, tumors with exon 20 insertions (Ex20ins) showed increased endothelial cell density, suggesting that these unique TME features may influence treatment outcomes across the various EGFR mutation subtypes.
The second study, executed in partnership with Dr. Paola Nisticò from the Regina Elena National Cancer Institute in Rome, Italy, utilized a combination of AI-driven insights and high-level spatial transcriptomics. Through this innovative approach, researchers examined tumors from 32 NSCLC patients treated with neoadjuvant chemo-immunotherapy. Findings revealed significantly distinct TME profiles: patients who attained a pathological complete response (pCR) demonstrated highly inflamed environments with organized tertiary lymphoid structures (TLS), while those who did not achieve pCR exhibited immune exclusion and a stroma rich in activated fibroblasts. This study underlined important immunological attributes tied to treatment responses, raising prospects for the identification of spatial biomarkers for better patient outcomes.
The final study centered on the development of an AI model predicting TP53 mutation status in lung adenocarcinoma using HE-stained images. This model was validated across a separate cohort of 462 cases and achieved notable results, with a 0.759 area under the receiver operating characteristic curve (AUROC), 82% sensitivity, and 63% specificity. Additionally, TME analysis indicated that TP53-mutated tumors tended to be more immune-inflamed in contrast to TP53-wild-type tumors, which revealed features like immune exclusion and higher densities of stromal fibroblasts and endothelial cells. Such findings confirm the potential for using HE-based AI as a screening mechanism, which could benefit patients eligible for clinical trials targeting specific TP53 variants.
Brandon Suh, CEO of Lunit, remarked on the implications of these studies, stating that they illustrate the vast potential of AI in delving deeper into lung cancer biology, bridging genomic analyses with TME characteristics and treatment outcomes. He emphasized Lunit's commitment to enhancing biomarker discovery and refining patient stratification, ultimately striving for more personalized therapeutic approaches for cancer patients.
Lunit's presentations at WCLC 2026 included:
- - Poster #P3.156: AI-Powered Tumor Microenvironment Analysis Across EGFR-Mutation Subtypes in Non-Small Cell Lung Cancer (Scheduled for September 15, 9:30 AM KST)
- - Poster #P2.126: Spatial Multi-Omics and AI-Driven Digital Pathology in Identifying Determinants of Pathological Response to Neoadjuvant Chemo-IO in NSCLC (September 14, 10:30 AM KST)
- - Poster #P2.134: Development of an HE-Based Genotype Predictor and Tumor Microenvironment Analysis of TP53-Mutated Lung Adenocarcinoma (September 14, 10:30 AM KST)
Founded in 2013, Lunit (KRX 328130) continues to lead the way in the fight against cancer through innovative AI solutions. From risk prediction to precision oncology, Lunit’s comprehensive offerings aim to improve early detection, treatment decisions, and outcomes throughout the cancer care continuum. As they enhance their AI platforms for better biomarker research and diagnostic capabilities, Lunit remains a pivotal force in global cancer care initiatives.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.